Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Jazz Pharmaceuticals' (JAZZ) Weak 4Q Results and 2016 Guidance Has Mizuho Securities Sidelined - PT to $124
February 24, 2016 6:54 AM ESTMizuho Securities reiterated a Neutral rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $124.00 (from $140.00), following the company's 4Q earnings report. JAZZ reported revenue of $340.9M and EPS of $2.60 versus consensus estimates of $350.8M and $2.60. Management also issued below-consensus 2016 guidance of... More
Jazz Pharmaceuticals (JAZZ) Reports In-Line Q4 EPS, FY Guidance Comes in Light
February 23, 2016 4:11 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.60, in-line with the analyst estimate of $2.60. Revenue for the quarter came in at $340.9 million versus the consensus estimate of $349.83 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2016 EPS of $10.90-$11.30, versus the consensus of $11.42. Jazz... More
